These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 17410031)

  • 21. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
    Zucali PA; Simonelli M; Michetti G; Tiseo M; Ceresoli GL; Collovà E; Follador A; Lo Dico M; Moretti A; De Vincenzo F; Lorenzi E; Perrino M; Giordano L; Farina G; Santoro A; Garassino M
    Lung Cancer; 2012 Mar; 75(3):360-7. PubMed ID: 21937142
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Second-line treatment for malignant pleural mesothelioma.
    Ceresoli GL; Zucali PA; Gianoncelli L; Lorenzi E; Santoro A
    Cancer Treat Rev; 2010 Feb; 36(1):24-32. PubMed ID: 19879055
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
    Scagliotti GV; Shin DM; Kindler HL; Vasconcelles MJ; Keppler U; Manegold C; Burris H; Gatzemeier U; Blatter J; Symanowski JT; Rusthoven JJ
    J Clin Oncol; 2003 Apr; 21(8):1556-61. PubMed ID: 12697881
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful salvage chemotherapy with gemcitabine and vinorelbine in a malignant pleural mesothelioma patient previously treated with pemetrexed.
    Agatsuma T; Koizumi T; Yasuo M; Urushihata K; Tsushima K; Yamamoto H; Hanaoka M; Fukushima M; Honda T; Kubo K
    Jpn J Clin Oncol; 2010 Dec; 40(12):1180-3. PubMed ID: 20603247
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effectiveness and safety of platinum-based pemetrexed and platinum-based gemcitabine treatment in patients with malignant pleural mesothelioma.
    Ak G; Metintas S; Akarsu M; Metintas M
    BMC Cancer; 2015 Jul; 15():510. PubMed ID: 26156324
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin.
    Giovannetti E; Zucali PA; Assaraf YG; Leon LG; Smid K; Alecci C; Giancola F; Destro A; Gianoncelli L; Lorenzi E; Roncalli M; Santoro A; Peters GJ
    Br J Cancer; 2011 Nov; 105(10):1542-53. PubMed ID: 21970874
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pemetrexed for malignant pleural mesothelioma: Is it a standard second-line therapy?
    Tamura K; Fujiwara Y
    Asia Pac J Clin Oncol; 2010 Dec; 6(4):248-50. PubMed ID: 21114772
    [No Abstract]   [Full Text] [Related]  

  • 28. Can pemetrexed help in malignant mesothelioma?
    Drug Ther Bull; 2006 Oct; 44(10):77-80. PubMed ID: 17067119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program.
    Jänne PA; Wozniak AJ; Belani CP; Keohan ML; Ross HJ; Polikoff JA; Mintzer DM; Ye Z; Monberg MJ; Obasaju CK;
    J Thorac Oncol; 2006 Jul; 1(6):506-12. PubMed ID: 17409909
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
    Dickgreber NJ; Fink TH; Latz JE; Hossain AM; Musib LC; Thomas M
    Clin Cancer Res; 2009 Jan; 15(1):382-9. PubMed ID: 19118069
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The value of pemetrexed for the treatment of malignant pleural mesothelioma: a comprehensive review.
    Boons CC; VAN Tulder MW; Burgers JA; Beckeringh JJ; Wagner C; Hugtenburg JG
    Anticancer Res; 2013 Sep; 33(9):3553-61. PubMed ID: 24023280
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pemetrexed and malignant pleural mesothelioma.
    Marangolo M; Vertogen B
    Ann Oncol; 2006 May; 17 Suppl 5():v103-5. PubMed ID: 16807435
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Third-line chemotherapy with carboplatin, gemcitabine and liposomised doxorubicin for malignant pleural mesothelioma.
    de Lima VA; Sørensen JB
    Med Oncol; 2015 Feb; 32(2):458. PubMed ID: 25572813
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience.
    Bearz A; Talamini R; Rossoni G; Santo A; de Pangher V; Fasola G; Rosetti F; Favaretto A; Gregorc V; Berretta M; Santarossa S; Berto E; Tirelli U
    BMC Res Notes; 2012 Sep; 5():482. PubMed ID: 22943698
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Carboplatin and pemetrexed in the management of malignant pleural mesothelioma: a realistic treatment option?
    Li L; Razak AR; Hughes A
    Lung Cancer; 2009 May; 64(2):207-10. PubMed ID: 18926592
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patients.
    Powrózek T; Kowalski DM; Krawczyk P; Ramlau R; Kucharczyk T; Kalinka-Warzocha E; Knetki-Wróblewska M; Winiarczyk K; Dyszkiewicz W; Krzakowski M; Milanowski J
    Clin Lung Cancer; 2014 Nov; 15(6):455-65. PubMed ID: 25246386
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pemetrexed (Alimta, MTA, multitargeted antifolate, LY231514) for malignant pleural mesothelioma.
    Manegold C
    Semin Oncol; 2003 Aug; 30(4 Suppl 10):32-6. PubMed ID: 12917819
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A case of malignant pleural mesothelioma that responded to cisplatin plus pemetrexed rechallenge].
    Shukuya T; Takahashi T; Nakamura Y; Yamamoto N
    Gan To Kagaku Ryoho; 2010 Mar; 37(3):487-90. PubMed ID: 20332689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systemic treatment of malignant pleural mesothelioma.
    Grosso F; Scagliotti GV
    Future Oncol; 2012 Mar; 8(3):293-305. PubMed ID: 22409465
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin.
    Zucali PA; Giovannetti E; Destro A; Mencoboni M; Ceresoli GL; Gianoncelli L; Lorenzi E; De Vincenzo F; Simonelli M; Perrino M; Bruzzone A; Thunnissen E; Tunesi G; Giordano L; Roncalli M; Peters GJ; Santoro A
    Clin Cancer Res; 2011 Apr; 17(8):2581-90. PubMed ID: 21262916
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.